Seminars in Hematology
Volume 44 , Pages S16-S20 , April 2007

Clinical Evaluation of Deferasirox (Exjade®, ICL670)

  • John Porter

      Affiliations

    • Corresponding Author InformationAddress correspondence to Professor John B Porter, MA, MD, FRCP, FRCPath, Department of Haematology, University College London, 98 Chenies Mews, London WC1E 6HX, UK.

References 

  1. Piga A, Galanello R, Forni G-L, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873–880
  2. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597–1602
  3. Galanello R, Piga A, Forni G-L, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in paediatric patients with β-thalassaemia major. Haematologica. 2006;91:1343–1351
  4. Cabantchik ZI, Breuer W, Zanninelli G, et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277–287
  5. Daar S, Taher A, Pathare A, et al. Deferasirox (Exjade®, ICL 670) provides 24-hour protection from labile plasma iron (LPI), in iron overloaded β-thalassaemia patients previously chelated with mono- or combination therapy. Haematologica. 2006;91(suppl 1, abstr):31
  6. Cappellini MD, Cohen A, Piga A, et al. A phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455–3462
  7. Vichinsky E, Fischer R, Fung E, et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade®, ICL670) is well tolerated and reduces iron burden. Blood. 2005;106(11, abstr):313
  8. Tchernia G, Vichinsky E, Jeng M, et al. The once-daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in Diamond-Blackfan anaemia patients. Haematologica. 2005;90(suppl 2):192
  9. Gattermann N, Cazzola M, Greenberg P, et al. The efficacy and tolerability of ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndrome (MDS) and iron overload. Leuk Res. 2005;29(suppl 1):S67
  10. Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2006;4:58–77
  11. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–2179
  12. Westwood MA, Anderson LJ, Tanner MA, et al. The relationship between myocardial iron deposition and left ventricular dysfunction in thalassemia using cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2005;7:46–47
  13. Eleftheriou P, Tanner M, Pennell D, et al. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis. Haematologica. 2006;91(suppl 1, abstr):999
  14. Cohen A, Masera G, Zoumbos N, et al. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade, ICL670). Blood. 2005;106(11, abstr):822
  15. Greenberg P, Dine G, Ganser A, et al. Deferasirox (Exjade®, ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia. Blood. 2005;106(11, abstr):2694
  16. Porter J, Borgna-Pignatti C, Baccarani M, et al. Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis. Blood. 2005;106(11, abstr):2690
  17. Forni GL, Piga A, Galanello R, et al. Growth and sexual development in pediatric patients treated over 48 weeks with ICL670, a once-daily oral iron chelator. Pediatr Blood Cancer. 2005;44(abstr):1106
  18. Brissot P, Turlin B, Forni G-L, et al. Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion-dependent anemia. Blood. 2005;106(11, abstr):823
  19. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567–573
  20. Cappellini MD, Bejaoui M, Agaoglu L, et al. Patient satisfaction with deferasirox (Exjade®, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood. 2005;106(11, abstr):2704
  21. Vichinsky E, Fischer R, Pakbaz Z, et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade®, ICL670) and deferoxamine (DFO). Blood. 2005;106(11, abstr):2334

PII: S0037-1963(07)00055-8

doi: 10.1053/j.seminhematol.2007.03.004

Seminars in Hematology
Volume 44 , Pages S16-S20 , April 2007

Article Tools

* Image Usage & Resolution